Valensa International obtains two US patents for joint health formulations

49e20df1-1551-4aa3-8258-f95e0101fefearticleimage.jpg

04 Oct 2017 --- The US Patent and Trademark Office has awarded Florida-based Valensa International two new patents, locking down patent protection for the core ingredients related to the company’s FlexPro MD and FlexPro ES. In clinical trials, these dietary formulations for joint health were shown to be three to five times more effective in relieving joint discomfort than a standard commercial formulation of glucosamine and chondroitin. 

The first of the two patents was granted for Flexuron Plus, Valensa’s proprietary, non-animal derived and highly-bioactive formula that features Medium-Chain Hyaluronic Acid (which has a lower molecular weight than traditional hyaluronic acid), when used in combination with the antioxidant Astaxanthin. Flexuron Plus is now available for licensing as a separate ingredient or finished product. 

The second patent was granted to Valensa for their bioavailable Zanthin Astaxanthin that has been coupled with Phospholipids. The Flexuron Plus blend of Zanthin Astaxanthin (a down-regulator of pro-inflammatory cytokines) and immunogenic hyaluronic acid, enhanced in the presence of phospholipid-based surfactants, has been clinically shown to dramatically reduce knee joint discomfort. In recent clinical trials, Valensa has demonstrated that this multi-patented blend works fast and has a cumulative beneficial effect over time on maximizing joint comfort.

Valensa’s joint formulations, including FlexPro MD and FlexPro ES, are available for multiple distribution channels, including retail mass market and specialty health stores.

According to Umasudhan C.P., CEO of Valensa, the ever-growing patent family protecting Flexuron Plus allows Valensa to develop the next generation of highly potent and mechanism-based joint formulations.

The human clinical study measuring the effectiveness of FlexPro MD, which contains Flexuron Plus, showed dramatic and nearly linear continuous improvement in joint discomfort over the 56-day clinical trial period. This trial showed that FlexPro MD was three to five times more effective in relieving joint discomfort than a standard commercial formulation of glucosamine and chondroitin (positive control arm) or the placebo control arm. Furthermore, joint discomfort began as early as seven days from trial initiation and by the end of the study subjects reported that they were essentially “pain-free.”

“Animal studies as well as in vitro cell culture work using real-time Polymerase Chain Reaction, or PCR, confirmed that our mechanism-based approach to product design was not only extremely effective and commercially rewarding, but also provided us with an extended vision into the design of even more potent and cost-effective next-generation joint healthcare products,” says Dr. John Minatelli, Sr. VP Business Development at Valensa who led the product development and clinical trials for FlexPro MD and Flexuron Plus.

In related news, Valensa International recently partnered up with Kemin Industries to jointly supply and market BetaVia ingredients, immune-supporting beta-glucans sourced from a proprietary strain of algae (Euglena gracilis), in the US dietary supplement and functional food and beverage markets. 

This partnership creates a two-armed sales approach to the US dietary supplement and functional foods and beverages markets. The Kemin sales team will service the functional food and beverage customers, while Valensa’s sales team will service customers producing dietary supplements.

“Valensa and its affiliate Parry Nutraceuticals are market leaders in microalgae-based supplements with well-established ingredient brands in over 30 countries,” Umasudhan C.P. says about the partnership. “The relationship with Kemin allows us to introduce novel immunity supplement formulations made stronger by BetaVia, to our omnichannel customer base in the US and internationally.”

Related Articles

Nutrition & Health News

Peruvian companies hope Europe goes nuts for its new “superseed” sacha inchi

22 Nov 2017 --- Peru is going to make a big effort to introduce sacha inchi to the European market this autumn. This is according to Andean & Amazonian Super(b) Foods, a news platform set up by the companies CBI, PromPeru, Adex and CCL to promote Peruvian foods. Sacha inchi is a nut-like seed with strong health benefits and the platform states that it “will be one of the stars of the Peruvian participations in Food Matters Live and Fi Europe this autumn.”

Nutrition & Health News

Researchers call for establishment of dietary reference intake for lutein

21 Nov 2017 --- Establishing a recommended dietary reference intake (DRI) value for lutein is “critically important” for advancing and improving public health, assert the authors of a new paper published online in the European Journal of Nutrition. “Lutein is ready to be considered for intake recommendations,” note the authors of the carotenoid found in egg yolks, colorful fruits and vegetables, and dietary supplements.

Business News

Gelita symposium paves a creative pathway to the future of food

21 Nov 2017 --- Nearly 80 delegates from a host of leading Food and Health & Nutrition companies last month made their way to Heidelberg (Germany) to attend Gelita’s latest International Food Symposium, “Off The Beaten Track, Inspiration for better food, nutrition and health,” where internationally renowned thought leaders from a variety of disciplines shared with attendees their insights into consumer behavior, ideas for digitizing food and knowledge of molecular developments in flavor perception and manipulation. 

Nutrition & Health News

Four claims in one vegan capsule: Polaris launches algal DHA omega 3 in softgel

21 Nov 2017 --- Polaris is launching its ultra-stable algal DHA omega 3 in vegan softgel format, enabling it to offer four EFSA claims in one capsule, the company reports. Each capsule is said to deliver an optimal 250mg of DHA omega 3 from microalgae in a 100 percent plant-based shell, making it the ideal solution for consumers seeking a vegan or vegetarian alternative to gelatin capsules.

Nutrition & Health News

Nestle reorganizes infant nutrition business, changes Executive Board

15 Nov 2017 --- The Nestlé Board of Directors has announced a change to the organization of the infant nutrition business at Nestlé to further improve the company’s “ability to win in this high-growth category.” Additionally, it will change its Executive Board, replacing its Executive Vice President and Chief Technology Officer and adjusting to the departure of its Deputy Executive Vice President in charge of Nestlé Nutrition. Effective January 1, 2018, infant nutrition will move from the globally managed Nestlé Nutrition to a regionally managed business. The change does not apply to other Nestlé businesses, the company adds.

More Articles
URL : http://www.nutritioninsight.com:80/news/category/Bone/Joint-Health.html